You are here:

emtricitabine/tenofovir disoproxil 200mg/245mg film-coated tablets (Truvada)

Advice

in the absence of a submission from the holder of the marketing authorisation:

emtricitabine / tenofovir disoproxil (Truvada®) is not recommended for use within NHS Scotland.

Indication under review: Treatment of HIV-1 infected adolescents aged 12 to <18 years with nucleoside reverse transcriptase inhibitor resistance or toxicities precluding the use of first line agents.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this setting.  As a result we cannot recommend its use within NHSScotland.

Drug Details

Drug Name: emtricitabine/tenofovir disoproxil 200mg/245mg film-coated tablets (Truvada)
SMC Drug ID: 1263/17
Manufacturer: Gilead Sciences Ltd
Indication: Treatment of HIV-1 infected adolescents aged 12 to <18 years with nucleoside reverse transcriptase inhibitor resistance or toxicities precluding the use of first line agents.
Submission Type: Non submission
Status: Not Recommended
Date Advice Published: 10 July 2017

Back